Bio Green Med Solution Inc (BGMS) FinancialsBGMSFinancialBio Green Med Solution Inc

Evaluating the bottom line, Bio Green Med Solution Inc maintains a gross margin of 23.51%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -124.40%, while the net margin is -120.54%. These profitability ratios, combined with a Return on Equity (ROE) of -171.64%, provide a clear picture of how effectively BGMS converts its operational activities into shareholder value.

In the context of the broader market, BGMS competes directly with industry leaders such as LIMN and PCSA. With a market capitalization of $5.05M, it holds a significant position in the sector. When comparing efficiency, BGMS's gross margin of 23.51% stands against LIMN's N/A and PCSA's N/A. Such benchmarking helps identify whether Bio Green Med Solution Inc is trading at a premium or discount relative to its financial performance.

The company reported total revenue of $778,000 in Q1 2026 and $336,000 in Q2 2026, but it has consistently posted net losses, including a loss of $405,000 in Q2 2026. The gross margin has improved slightly to 23.51% in Q2 2026, but overall financial performance remains weak.